Skip to main content

Evaluation of recombinant sporozoite antigen SPAG-1 as a vaccine candidate against Theileria annulata by the use of different delivery systems

Buy Article:

$51.00 plus tax (Refund Policy)

Summary

The major sporozoite surface antigen of Theileria annulata (SPAG-1) is a candidate for inclusion in a subunit vaccine. In this paper we summarize the results of 4 vaccination experiments using recombinant SPAG-1 expressed in different systems and presented in different adjuvants. The antigen has been presented as either a C terminal 108 amino acid peptide (called SR1) expressed as both β-galactosidase and hepatitis B core antigen fusions or as a full-length form expressed as a GST fusion with an N terminal His6 tag. We used different adjuvants, namely Freund's, saponin, ISCOMs and a proprietary adjuvant supplied by SmithKline Beecham, which we call SKBA. The data point to the conclusion that SPAG-1 can elicit partial protection and is therefore suitable for inclusion in an eventual multicomponent subunit vaccine.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Theileria annulata; protection; sporozoite antigen (SPAG-1); vaccine

Document Type: Research Article

Affiliations: 1: Department of Biology, University of York, UK 2: Centre for Tropical Veterinary Medicine, University of Edinburgh, UK 3: Roslin Institute, UK 4: International Livestock Research Institute, Kenya 5: Department of Parasitology and Tropical Veterinary Medicine, University of Utrecht, The Netherlands

Publication date: 1999-09-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more